Adam Levy, MD
Gastroenterology · Macon, GANPI 1851504989
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,670 of the $44,087 with a category attached, or 74.1%. 40 manufacturers reported payments, led by AbbVie at 44.0% of the total. Reporting peaked in 2024 at $19,559 and has fallen 83.5% since, to $3,226 in 2025. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 433 payments — averaging $101.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Phathom Pharmaceuticals, Inc.$18K
- AstraZeneca$2K
- Sanofi$540
- Takeda Pharmaceuticals U.S.A., Inc.$448
- Johnson & Johnson$401
- plus $4K from 34 others
What the payments were for
- Consulting fees$1,8604%
- Speaking & faculty fees$32,67074%
- Travel & lodging$1,1603%
- Food & beverage$8,37419%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 161 | $19,393 |
| Phathom Pharmaceuticals, Inc. | 47 | $17,860 |
| AstraZeneca(2 entities) | 2 | $1,880 |
| Sanofi | 21 | $540 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $448 |
| Johnson & Johnson | 21 | $401 |
| Regeneron Healthcare Solutions, Inc. | 14 | $380 |
| Pfizer | 13 | $346 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $340 |
| Bristol Myers Squibb | 21 | $268 |
| E.r. Squibb & Sons, L.L.C. | 2 | $207 |
| Ipsen Biopharmaceuticals, Inc | 4 | $167 |
| Ironwood Pharmaceuticals, Inc | 11 | $157 |
| Ardelyx, Inc. | 7 | $145 |
| Regeneron | 1 | $142 |
| Ferring Pharmaceuticals Inc. | 10 | $137 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Stryker | 3 | $117 |
| Intercept Pharmaceuticals, Inc. | 6 | $113 |
| Novo Nordisk | 1 | $94 |
| QOL Medical, LLC | 7 | $91 |
| Madrigal Pharmaceuticals | 3 | $73 |
| Organon | 4 | $67 |
| Covidien LP | 1 | $67 |
| Nevro Corp. | 1 | $67 |
| Daiichi Sankyo Inc. | 2 | $58 |
| Merck | 3 | $55 |
| Gilead | 3 | $53 |
| Lilly USA, LLC | 2 | $43 |
| UCB, Inc. | 3 | $40 |
| EKOS Corporation | 2 | $36 |
| Concordia Pharmaceuticals Inc. | 1 | $28 |
| Redhill Biopharma Inc. | 2 | $26 |
| Orphalan Inc | 1 | $22 |
| Dentsply IH AB | 1 | $21 |
| Medtronic | 1 | $19 |
| Shionogi Inc | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Intra-sana Laboratories | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,087 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 36 | $956,469 |
| ZeposiaOzanimod Hydrochloride | 15 | $135,983 |
| EntyvioVedolizumab | 12 | $113,055 |
| CreonLipase/Protease/Amylase | 18 | $61,371 |
| ZenpepLipase/Protease/Amylase | 12 | $54,961 |
| LinzessLinaclotide | 32 | $35,652 |
| MovantikNaloxegol Oxalate | 17 | $11,622 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 217 | $3,688 |
| Sucralfate | 56 | $2,658 |
| Lubiprostone | 16 | $2,036 |
| Omeprazole | 229 | $1,683 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,582 |
| Budesonide DrBudesonide | 11 | $1,459 |
| Pantoprazole Sodium | 117 | $1,340 |
| Esomeprazole Magnesium | 40 | $1,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $401 | $956,46936 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $207 | $135,98315 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $448 | $113,05512 claims |
| AbbVieCreon, Linzess | $19,393 | $97,02350 claims |
| Redhill Biopharma Inc.Movantik | $26 | $11,62217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Macon
- Daniel Eli PennMacon$92K
- Joel JudahMacon$18K
- Raymond BedgoodMacon$17K
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Satish RaoAugusta$335K
- Roshan ShresthaAtlanta$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.